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Abstract
Background: Mid-ventricular obstructive hypertrophic cardiomyopathy (MVOHC) is a rare type
of cardiomyopathy. The diagnosis is based on the hourglass appearance on the left ventriculogram
and the presence of pressure gradient between apical and basal chamber of the ventriculum on the
hemodynamic assessment.
Case presentation: The present case represents successful percutaneous treatment with septal
ablation to patient with MVOHC associated with systolic anterior motion of the mitral valve and
obstruction at both the mid-ventricular and outflow levels.
Conclusion: Alcohol septal ablation has been proposed as less invasive alternatives to surgery in
patients with MVOHC.
Background
Hypertrophic cardiomyopathy (HC) is a hereditary myo-
cardial disorder, caused by mutations of sarcomeric pro-
teins [1]. In roughly 25% of cases of HC there is associated
obstruction to left ventricular (LV) outflow [1]. Obstruc-
tion can occur at several locations within the ventricle,
depending on the distribution of hypertrophy, including
a) the mitral valve level in association with systolic ante-
rior motion (SAM) of the mitral valve; b) the mid-ventri-
cle; or c) within the cardiac apex [1].
In about 5% of patients a mid-ventricular obstruction
(MVO) can be observed [2]. These patients are often
symptomatic from hemodynamic causes and are also
prone to symptomatic and even lethal ventricular arrhyth-
mias. MVO may be associated with hypertrophy of the
papillary muscle(s) and apical LV aneurysm. MVO usually
presents as local obstruction but can be associated with
SAM and obstruction at both the mid-cavitary and out-
flow levels [1].
During the past 10 years, atrio-ventricular sequential pac-
ing and alcohol septal ablation have been proposed as less
invasive alternatives to surgery for patients who fail to
respond to pharmacologic therapy [3,4]. However, atrio-
ventricular sequential pacing is not currently thought to
be dramatically beneficial [5,6]. We report on percutane-
ous septal ablation in a patient with left mid-ventricular
obstructive hypertrophic cardiomyopathy (MVOHC)
associated with SAM of the mitral valve and obstruction at
both the mid-ventricular and outflow levels, which seems
to be an alternative therapy in these patients.
Case presentation
A 34-year-old man with HC (primarily diagnosed 6 years
ago) was referred to our clinic with the complaints of pal-
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pitation, chest pain and dyspnea on exertion, despite
medication with 200 mg metoprolol daily. His functional
capacity was New York Heart Association (NYHA) class
III. He had no family history of HC. The fourth heart
sound and moderate systolic murmur in mitral area radi-
ating to mid-clavicular line were heard at cardiac ausculta-
tion. On electrocardiogram, sinus rhythm, left axis
deviation and repolarization abnormalities (negative T
vawes) were seen. Chest X-ray showed neither cardiomeg-
aly nor pulmonary congestion. Echocardiographic exami-
nation was done to assess the LV anatomy and revealed
normal dimensions of the LV at end-diastole (41 mm)
and end-systole (19 mm), SAM of the mitral valve with
moderate mitral regurgitation, left atrial dilatation (55
mm) and hypertrophic interventricular septum (mid:25
mm, basal:27 mm). LV ejection fraction was 75%. Con-
tinuous-wave Doppler measurements showed a peak
systolic resting gradient of 46 mmHg, with an increase to
96 mmHg at Valsalva's maneouvre at the LV outflow (Fig-
ure 1A). Coronary angiography and invasive hemody-
namic assessment were done. Coronary angiograms
showed no narrowing of major epicardial coronary arter-
ies. The left ventriculography showed a hyperkinetic con-
traction pattern at the mid-ventricle with a narrow
muscular tunnel between the LV apical and bazal cavities
(Figure 1B). Hemodynamic assessment revealed a signifi-
cant intra-ventricular pressure gradient of 56 mmHg (LV
apex 178/10 mmHg, LV outflow 122/12 mmHg) with
mild LV outflow tract pressure gradient of 30 mmHg
(aorta 92/64) (Figure 2A). We finally diagnosed MVOHC
associated with SAM of the mitral valve and obstruction at
both the mid-ventricular and outflow levels.
The patient was informed about the therapeutic options
and gave her written consent to percutaneous septal myo-
cardial ablation. The first septal branch was dominant
(diameter: 2.1 mm) and showed prominent septal myo-
cardial distribution (Figure 1C). The distance between the
left anterior descending coronary artery ostium and the
origin of the first septal branch was 24.4 mm. Other distal
septal branches were very small. It was considered that the
first septal branch ablation may be effective in decreasing
the intraventricular pressure gradient. The procedure was
performed as described elsewhere [7]. The floppy wire
(Choice scimed guide wire, 0.014", 300 cm, Boston Scien-
tific, Miami, USA) was crossed to first septal branch which
estimated target vessel. A 2.5 × 20 mm over the wire bal-
loon (Maverick OTW PTCA dilatation catheter, Boston
Scientific, Maple Grove, USA) was placed in the proximal
part of the vessel. The echo contrast agent (Echovist,
Schering) was administered selectively in the estimated
vessel under simultaneous color Doppler echocardiogra-
phy. Prior to alcohol injection, balloon position was veri-
fied by myocardial contrast echocardiography (Figure
3A). When the balloon was inflated and transient occlu-
sion constituted, hemodynamic measurements were
repeated. After that demonstrating the significant reduc-
tion in intra-ventricular pressure gradient, the vessel was
occluded by injection of 3 cc absolute alcohol in portions
of 1 cc/min. (Figure 3B). Repeated hemodynamic meas-
urements found a decrease of the post-extrasystolic gradi-
ent to 18 mmHg at the mid-ventricular level with no
resting gradient in the LV outflow level (Figure 2B).
Patient had slight chest pain during the procedure. Com-
plications such as conduction abnormality were not seen.
The post-procedural electrocardiogram showed ST seg-
ment elevation (maximal 6 mm) in V1–2 with reciprocal ST
segment depression in II, III and aVF. Maximal creatine
kinase rise was 1591 U/l with a MB fraction of 347 U/l.
The size of the caused infarction was estimated by areas
under the CPK-MB versus time graph's curve. SAS 9.1 sta-
tistical software was used to calculate area under the curve.
Area under the curve was 5070 U/L hour for CPK-MB (Fig-
ure 4).
A: Pre-procedural invasive pressure recordings, B: Post-pro- cedural invasive pressure recordings Figure 2
A: Pre-procedural invasive pressure recordings, B: Post-pro-
cedural invasive pressure recordings.
A: Pre-procedural continuous-wave Doppler recordings, B:  Hyperkinetic left ventricle, C: Dominant first septal branch Figure 1
A: Pre-procedural continuous-wave Doppler recordings, B: 
Hyperkinetic left ventricle, C: Dominant first septal branch.BMC Cardiovascular Disorders 2006, 6:15 http://www.biomedcentral.com/1471-2261/6/15
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The post-procedural echocardiographic examination was
done before the discharge and showed reductions of left
atrial dimension to 46 mm and interventricular septum
thickness to 20 mm with septal hypokinesia and mild
mitral regurgitation without SAM of the mitral valve. LV
end-diastolic and end-systolic diameters were 49 mm, 32
mm respectively. Continuous-wave Doppler measure-
ments showed 21 mmHg a peak systolic resting gradient,
with an increase to 36 mmHg at Valsalva's maneouvre
(Figure 3C). The patient was discharged after an unevent-
ful hospital stay of 5 days. Medication with 100 mg meto-
prolol was continued at discharge.
At 6 months' follow-up, the patient was asymptomatic
and her functional capacity was improved (NYHA class I).
Physical examination showed mild systolic murmur in
mitral area. The electrocardiogram showed sinus rhythm,
left axis and no Q wave in V1–2 (Figure 5A). The control
echocardiographic examination showed reduction of
interventricular septum thickness (mid:18 mm, basal:16
mm, Figure 5B) and mild mitral regurgitation without
SAM of the mitral valve. LV ejection fraction was 67%.
Continuous-wave Doppler measurements showed 18
mmHg peak systolic resting gradient, with an increase to
31 mmHg at Valsalva's maneouvre (Figure 5C).
Conclusion
Obstruction at lower levels of the ventricle simply reflects
partial obliteration of the ventricular cavity by the con-
tracting hypertrophied muscle in the face of continued
ejection of blood. An asynergic or aneurismal apical
chamber in the absence of fixed coronary artery disease
has been previously described in patients with MVO [8].
It has been suggested that the development of apical aneu-
rysm may be secondary to increased afterload and high
apical pressure resulting from a systolic MVO [9]. There-
fore, relief of the high apical pressure may be necessary
preventing further asynergy.
Myectomy has been employed primarily in patients with
obstruction at the mitral valve level. Because obstruction
primarily relates to SAM of the mitral valve, some have
recommended mitral valve replacement as the most direct
method for relieving obstruction [1]. Mitral valve replace-
ment has also been recommended for patients with direct
insertion of the papillary muscle into the anterior mitral
leaflet and associated MVO, although this strategy is
undesirable for young patients. In these cases, extending
and broadening the myectomy in the mid-ventricle and
mobilizing the papillary muscle with valve preservation
has been reported with good success [1].
Non-surgical treatment options for the obstructive cardio-
myopathies are performed to increasing number of
patients to reduce hospitalization duration and cost. With
DDD pacing the outflow gradient can be reduced more
than 30%. Randomized trials have shown a limited
hemodynamic and clinical improvement in severely
symptomatic patients with hypertrophic obstructive car-
diomyopathy [10]. Although there are a few report of a
therapeutic effect of DDD pacing in MVO [11,12], it can
not be recommended for routine application due to fail-
ure of reliable predictability of individual therapeutic suc-
cess [5].
Nonrandomized reports comparing septal ablation with
myectomy describe similar degrees of LV outflow tract gradi-
ent reduction with follow-up between 3 months and 1 year
[13]. Additionally, improvements in clinical endpoints, such
as quality of life and functional status, have been compara-
The size of the caused infarction estimated by areas under  the CPK-MB versus time graph's curve Figure 4
The size of the caused infarction estimated by areas under 
the CPK-MB versus time graph's curve.
A: The echocontrast appearance in hypertrophic muscle seg- ment, B: No angiographic appearance after alcohol injection  in first septal branch (Black arrow), C: Post-procedural con- tinuous-wave Doppler recordings Figure 3
A: The echocontrast appearance in hypertrophic muscle seg-
ment, B: No angiographic appearance after alcohol injection 
in first septal branch (Black arrow), C: Post-procedural con-
tinuous-wave Doppler recordings.BMC Cardiovascular Disorders 2006, 6:15 http://www.biomedcentral.com/1471-2261/6/15
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ble, suggesting that septal ablation is a safe and effective alter-
native to myectomy in select patients. However, occlusion of
the septal branches is generally ineffective for reducing the
intra-ventricular pressure gradient if they do not supply the
obstructive muscle mass. The most important problem is the
identification of the target vessel. Variability in the size and
distribution of the first septal branch in patients with HC is
substantial. Areas of the heart other than the basal septum are
supplied in some patients by the first septal branch. In other
patients the first septal branch is not supply the entire basal
septum. A detailed evaluation of the distribution of the first
septal branch may be necessary in all patients with HC who
are undergoing alcohol septal ablation [14]. Echocardio-
graphic monitoring is indispensable in order to identify the
target vessel and to exclude alcohol misplacements.
The fourth septal branch ablation for pressure gradient
reduction in patients with MVOHC has been reported by
Seggewiss et al [15]. The present case had MVOHC associ-
ated with SAM of the mitral valve and obstruction at both
the mid-ventricular and outflow levels. In addition, the
first septal branch was pretty dominant and considered
that alcohol ablation can be effective in decreasing the
intra-ventricular pressure gradient. Likewise, the echocon-
trast injection in the first septal branch resulted with the
largest echocontrast view in hypertrophic muscle seg-
ment. Furthermore, transient occlusion of the vessel by
balloon inflation resulted in significant decrease in intra-
ventricular pressure gradient. Therefore, the first septal
branch was assumed as a target vessel and occlusion of the
vessel resulted with a significant and sustained reduction
of symptoms.
There are multiple factors cause severe arrhythmias during
the procedure, including ischemia, infarction, and the
presence of an arrhythmogenic myofibrillar substrate,
local-tissue toxicity from the alcohol and echocontrast
agent. Although were not seen in our case, total AV block
and ventricular fibrillation may occur with application of
echovist in the systemic arterial circulation. Therefore, lev-
ovist is appropriate echo contrast agent for septal ablation
[16]. Development of LV myocardial damage, heart fail-
ure, ventricular septal defect, dysfunction of papillary
muscles and severe rhythm disturbances such as perma-
nent or transient atrioventricular block required pace-
maker implantation are important limitations of this
procedure [17].
In summary, percutaneous septal ablation may be useful
in patients with MVOHC accompanying with LV outflow
tract obstruction. Echocardiographic monitoring in alco-
hol induced percutaneous myocardial ablation enables
the widening of morphological indication to patients
with MVOHC. Septal ablation in MVOHC is not classical
and wide accepted treatment in contrast to the subaortic
type LV obstruction. Possible complications and
unknown long-term effects require careful patient selec-
tion as well as experience in interventional cardiology and
hypertrophic cardiomyopathy.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
IT, EE drafting the article, performed percutaneous inter-
vention, critical revision of the article, and final approval
of the version.
EA, UOT echocardiographic examinations.
All authors read and approved the final manuscript.
References
1. Yoerger DM, Weyman AE: Hypertrophic obstructive cardiomy-
opathy: mechanism of obstruction and response to therapy.
Rev Cardiovasc Med 2003, 4:199-215.
2. Wigle ED, Rakowski H: Hypertrophic cardiomyopathy: when
do you diagnose midventricular obstruction versus apical
cavity obliteration with a small nonobliterated area at the
apex of the left ventricle?  J Am Coll Cardiol 1992, 19:525-526.
3. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH 3rd: A
prospective follow-up of alcohol septal ablation for sympto-
matic hypertrophic obstructive cardiomyopathy – the Bay-
lor experience (1996–2002).  Clin Cardiol 2005, 28:124-130.
4. Kappenberger LJ, Linde C, Jeanrenaud X, Daubert C, McKenna W,
Meisel E, Sadoul N, Chojnowska L, Guize L, Gras D, Aebischer N,
Gadler F, Ryden L: Clinical progress after randomized on/off
pacemaker treatment for hypertrophic obstructive cardio-
myopathy. Pacing in Cardiomyopathy (PIC) Study Group.
Europace 1999, 2:77-84.
5. Dimitrow PP, Podolec P, Grodecki J, Plazak W, Dudek D, Pieniazek
P, Bacior B, Legutko J, Olszowska M, Kostkiewicz M, Kawecka-Jaszcz
K, Tracz W, Dubiel JS: Comparison of dual-chamber pacing
with nonsurgical septal reduction effect in patients with
hypertrophic obstructive cardiomyopathy.  Int J Cardiol 2004,
94:31-34.
6. Gietzen FH, Schummelfeder J, Neuser H, Brunn J, Schumacher B, Ker-
ber S: Interventional Treatment in Hypertrophic Cardiomy-
opathy.  Herz 2005, 30:102-110.
7. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK,
Strick S: Percutaneous transluminal septal myocardial abla-
A: Post procedural ECG, B: Post-procedural apical 4 cham- ber view after six months, C: Continuous-wave Doppler  recordings after six months Figure 5
A: Post procedural ECG, B: Post-procedural apical 4 cham-
ber view after six months, C: Continuous-wave Doppler 
recordings after six months.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cardiovascular Disorders 2006, 6:15 http://www.biomedcentral.com/1471-2261/6/15
Page 5 of 5
(page number not for citation purposes)
tion in hypertrophic obstructive cardiomyopathy: acute
results and 3-month follow-up in 25 patients.  J Am Coll Cardiol
1998, 31:252-258.
8. Nakamura T, Matsubara K, Furukawa K, Azuma A, Sugihara H, Kat-
sume H, Nakagawa M: Diastolic paradoxic jet flow in patients
with hypertrophic cardiomyopathy: Evidence of concealed
apical asynergy with cavity obliteration.  J Am Coll Cardiol 1992,
19:516-524.
9. Fighali S, Krajcer Z, Edelman S, Leachman RD: Progression of
hypertrophic cardiomyopathy into a hypokinetic left ventri-
cle: High incidence in patients with midventricular obstruc-
tion.  J Am Coll Cardiol 1987, 9:288-294.
10. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes
SN, Allison TG, Tajik AJ: Dual-chamber pacing for hypertrophic
cardiomyopathy: A randomized, double blind, crossover
trial.  J Am Coll Cardiol 1997, 29:435-441.
11. Watanabe H, Kibira S, Saito T, Shimizu H, Abe T, Nakajima I, Iino K,
Miura M: Beneficial effect of dual-chamber pacing for a left
mid-ventricular obstruction with apical aneurysm.  Circ J 2002,
66:981-984.
12. Begley D, Mohiddin S, Fananapazir L: Dual chamber pacemaker
therapy for mid-cavity obstructive hypertrophic cardiomy-
opathy.  Pacing Clin Electrophysiol 2001, 24:1639-1644.
13. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV,
Danielson GK, Quinones MA, Tajik AJ, Spencer WH: Comparison
of ethanol septal reduction therapy with surgical myectomy
for the treatment of hypertrophic obstructive cardiomyopa-
thy.  J Am Coll Cardiol 2001, 38:1701-1706.
14. Singh M, Edwards WD, Holmes DR Jr, Tajil AJ, Nishimura RA: Anat-
omy of the first septal perforating artery: a study with impli-
cations for ablation therapy for hypertrophic
cardiomyopathy.  Mayo Clin Proc 2001, 76:799-802.
15. Seggewiss H, Faber L: Percutaneous septal ablation for hyper-
trophic cardiomyopathy and mid-ventricular obstruction.
Eur J Echocardiogr 2000, 1:277-280.
16. Becher H: Contrast echocardiography: clinical applications
and future prospects.  Herz 2001, 27:201-216.
17. Zhang W, Li Z, Zhang M, Yuan L, Guan R, Hou A, Jin Y, Deng Z:
Complications of percutaneous transluminal septal myocar-
dial ablation in hypertrophic obstructive cardiomyopathy.
Chin Med J (Engl) 2002, 115:1283-1286.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2261/6/15/prepub